Vardenafil: A Potential Drug To Protect Gastric MucosaMain Category: GastroIntestinal / GastroenterologyArticle Date: 19 Nov 2009 Indomethacin has been proved by epidemiological and experimental studies to be closely associated with peptic ulcer development. Vardenafil is a potent phosphodiesterase 5 inhibitor and its effects on the gastric mucosa have not been reported. A research article published in the World Journal of Gastroenterology addresses this problem. The research team, led by Dr. Karakaya MD from Zonguldak Karaelmas University, designed an experimental study in rats in which they used vardenafil to study gastric mucosal protection against the harmful effects of indomethacin. Multiple agents have been used to prevent NSAID-induced peptic ulcer. This work is the first experimental study that shows the beneficial effects of Vardenafil (a phosphodiesterase type V inhibitor) on NSAID-induced gastric ulcer. The gastroprotective effect of vardenafil against NSAID-induced peptic ulcer is dose-dependent. The study results suggest that vardenafil might be used as a potential therapeutic drug to prevent NSAID-induced gastric ulcer formation. Reference: Karakaya K, Hanci V, Bektas S, Can M, Ucan HB, Emre AU, Tascılar O, Ozkocak Turan I, Comert M, Irkorucu O, Karadeniz Cakmak G. Mitigation of indomethacin-induced gastric mucosal lesions by a potent specific type V phosphodiesterase inhibitor. World J Gastroenterol 2009; 15(40): 5091-5096 http://www.wjgnet.com/1007-9327/15/5091.asp Source: Lin Tian World Journal of Gastroenterology Original article posted on Medical News Today. Articles not to be reproduced without permission of Medical News Today Medical News Today publishes the latest health news and health videos for consumers and health professionals. It has a searchable archive of over 100,000 health news articles. < back to medical news
|
||||
|





